Quick Answer
Altamira Therapeutics Ltd. reported Net Income of -$8.20 million for fiscal year 2020.
Altamira Therapeutics Ltd. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Net Income | — | — | — | — | -$8.20M -23.6% |
-$6.63M +42.3% |
| Total Assets | $8.65M -5.4% |
$9.14M +34.2% |
$6.81M -64.5% |
$19.17M -7.8% |
$20.80M +125.4% |
$9.23M -6.6% |
| Stockholders Equity | — | — | — | — | $16.77M +177.8% |
$6.04M |
| R&D Expense | $3.73M +10.3% |
$3.38M -77.9% |
$15.31M +378.1% |
$3.20M +11.9% |
$2.86M -13.9% |
$3.33M -50.3% |
| Gross Profit | — | — | -$1.14M +47.7% |
-$2.18M | — | — |
- Altamira Therapeutics Ltd. reported Net Income of -$8.20 million for fiscal year 2020.
- Altamira Therapeutics Ltd. showed a decrease of -23.6% in Net Income compared to the prior fiscal year.
- Altamira Therapeutics Ltd. reported Total Assets of $8.65 million for fiscal year 2024.
- Altamira Therapeutics Ltd. showed a decrease of -5.4% in Total Assets compared to the prior fiscal year.
- Altamira Therapeutics Ltd. reported Stockholders Equity of $16.77 million for fiscal year 2020.
- Altamira Therapeutics Ltd. showed an increase of +177.8% in Stockholders Equity compared to the prior fiscal year.
- Altamira Therapeutics Ltd. reported R&D Expense of $3.73 million for fiscal year 2024.
- Altamira Therapeutics Ltd. showed an increase of +10.3% in R&D Expense compared to the prior fiscal year.
- Altamira Therapeutics Ltd. reported Gross Profit of -$1.14 million for fiscal year 2022.
- Altamira Therapeutics Ltd. showed an increase of +47.7% in Gross Profit compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: